Pharmacogenetics to Avoid Adverse Drug Reactions
Adverse drug reactions are one of the major constraints when using drugs. These adverse reactions can impact healthcare systems as strongly as many prevalent diseases. Identifying DNA variants associated with adverse drug reactions can help personalize medicine and sustain healthcare systems. This b...
Saved in:
| Format: | Online |
|---|---|
| Language: | English |
| Published: |
MDPI - Multidisciplinary Digital Publishing Institute
2022
|
| Subjects: | |
| Online Access: | ONIX_20220321_9783036533445_90 |
| Tags: |
No Tags, Be the first to tag this record!
|
| _version_ | 1869518339537108992 |
|---|---|
| collection | Directory of Open Access Books |
| description | Adverse drug reactions are one of the major constraints when using drugs. These adverse reactions can impact healthcare systems as strongly as many prevalent diseases. Identifying DNA variants associated with adverse drug reactions can help personalize medicine and sustain healthcare systems. This book delves into new advances in pharmacogenetics of cardiovascular, cancer, and nervous system drugs. It may be useful for clinicians and patients to understand the basics of pharmacogenetics. |
| format | Online |
| id | doab-20.500.12854ir-79654 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2022 |
| publishDateRange | 2022 |
| publishDateSort | 2022 |
| publisher | MDPI - Multidisciplinary Digital Publishing Institute |
| publisherStr | MDPI - Multidisciplinary Digital Publishing Institute |
| record_format | ojs |
| spelling | doab-20.500.12854ir-796542024-03-30T23:22:17Z Pharmacogenetics to Avoid Adverse Drug Reactions López-Fernández, Luis A. 5-fluorouracil capecitabine fluoropyrimidine thymidylate synthase thymidylate synthase enhancer region upstream stimulatory factor 1 adverse drug reactions pharmacogenomics epistasis random forest statin cardiovascular disease colorectal cancer personalised medicine toxicity (es)citalopram drug-gene-interaction drug-drug-interaction drug-drug-gene-interaction the PharmLines initiative antipsychotic agents pharmacogenetics cytochrome P-450 enzyme system psychotic disorders precision medicine direct oral anticoagulants clinical implementation atorvastatin SLCO1B1 HLA cutaneous adverse drug reaction SCAR genetic polymorphism antiepileptics CYP450 enzymes platelet reactivity single-nucleotide variants acute coronary syndrome clopidogrel genotype allele polymorphism HLA B CYP2C9*3 cutaneous adverse drug reactions (CADRs) anti-epileptic drugs (AEDS) phenytoin (PHT) genetic risk factors South India India cardiology adverse events guidelines n/a thema EDItEUR::M Medicine and Nursing Adverse drug reactions are one of the major constraints when using drugs. These adverse reactions can impact healthcare systems as strongly as many prevalent diseases. Identifying DNA variants associated with adverse drug reactions can help personalize medicine and sustain healthcare systems. This book delves into new advances in pharmacogenetics of cardiovascular, cancer, and nervous system drugs. It may be useful for clinicians and patients to understand the basics of pharmacogenetics. 2022-03-21T16:29:33Z 2022-03-21T16:29:33Z 2022 book ONIX_20220321_9783036533445_90 9783036533445 9783036533438 https://directory.doabooks.org/handle/20.500.12854/79654 eng image/jpeg Attribution 4.0 International https://mdpi.com/books/pdfview/book/5039 https://mdpi.com/books/pdfview/book/5039 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-0365-3343-8 10.3390/books978-3-0365-3343-8 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783036533445 9783036533438 220 Basel open access |
| spellingShingle | 5-fluorouracil capecitabine fluoropyrimidine thymidylate synthase thymidylate synthase enhancer region upstream stimulatory factor 1 adverse drug reactions pharmacogenomics epistasis random forest statin cardiovascular disease colorectal cancer personalised medicine toxicity (es)citalopram drug-gene-interaction drug-drug-interaction drug-drug-gene-interaction the PharmLines initiative antipsychotic agents pharmacogenetics cytochrome P-450 enzyme system psychotic disorders precision medicine direct oral anticoagulants clinical implementation atorvastatin SLCO1B1 HLA cutaneous adverse drug reaction SCAR genetic polymorphism antiepileptics CYP450 enzymes platelet reactivity single-nucleotide variants acute coronary syndrome clopidogrel genotype allele polymorphism HLA B CYP2C9*3 cutaneous adverse drug reactions (CADRs) anti-epileptic drugs (AEDS) phenytoin (PHT) genetic risk factors South India India cardiology adverse events guidelines n/a thema EDItEUR::M Medicine and Nursing Pharmacogenetics to Avoid Adverse Drug Reactions |
| title | Pharmacogenetics to Avoid Adverse Drug Reactions |
| title_full | Pharmacogenetics to Avoid Adverse Drug Reactions |
| title_fullStr | Pharmacogenetics to Avoid Adverse Drug Reactions |
| title_full_unstemmed | Pharmacogenetics to Avoid Adverse Drug Reactions |
| title_short | Pharmacogenetics to Avoid Adverse Drug Reactions |
| title_sort | pharmacogenetics to avoid adverse drug reactions |
| topic | 5-fluorouracil capecitabine fluoropyrimidine thymidylate synthase thymidylate synthase enhancer region upstream stimulatory factor 1 adverse drug reactions pharmacogenomics epistasis random forest statin cardiovascular disease colorectal cancer personalised medicine toxicity (es)citalopram drug-gene-interaction drug-drug-interaction drug-drug-gene-interaction the PharmLines initiative antipsychotic agents pharmacogenetics cytochrome P-450 enzyme system psychotic disorders precision medicine direct oral anticoagulants clinical implementation atorvastatin SLCO1B1 HLA cutaneous adverse drug reaction SCAR genetic polymorphism antiepileptics CYP450 enzymes platelet reactivity single-nucleotide variants acute coronary syndrome clopidogrel genotype allele polymorphism HLA B CYP2C9*3 cutaneous adverse drug reactions (CADRs) anti-epileptic drugs (AEDS) phenytoin (PHT) genetic risk factors South India India cardiology adverse events guidelines n/a thema EDItEUR::M Medicine and Nursing |
| topic_facet | 5-fluorouracil capecitabine fluoropyrimidine thymidylate synthase thymidylate synthase enhancer region upstream stimulatory factor 1 adverse drug reactions pharmacogenomics epistasis random forest statin cardiovascular disease colorectal cancer personalised medicine toxicity (es)citalopram drug-gene-interaction drug-drug-interaction drug-drug-gene-interaction the PharmLines initiative antipsychotic agents pharmacogenetics cytochrome P-450 enzyme system psychotic disorders precision medicine direct oral anticoagulants clinical implementation atorvastatin SLCO1B1 HLA cutaneous adverse drug reaction SCAR genetic polymorphism antiepileptics CYP450 enzymes platelet reactivity single-nucleotide variants acute coronary syndrome clopidogrel genotype allele polymorphism HLA B CYP2C9*3 cutaneous adverse drug reactions (CADRs) anti-epileptic drugs (AEDS) phenytoin (PHT) genetic risk factors South India India cardiology adverse events guidelines n/a thema EDItEUR::M Medicine and Nursing |
| url | ONIX_20220321_9783036533445_90 |